Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials

Table 4

Clinical trials on treatment with donepezil in moderate-severe AD.

First author and number in the list of references	Severity	Mean age years	Mean MMSE at baseline	Duration; of the study	𝑁	Test
Carrasco et al. 2011 [23]	MMSE 1–23	74.4 (7.7)	Mild: 20.14 (4); Moderate: 15.9 (3.83); Severe: 11.3 (5.4)	6 months	455	MMSE; NPI
Farlow et al. 2011, 2010 [24, 25]	MMSE 0–20	10 mg: 73.8 (8.56); 23 mg: 73.9 (8.53)	10 mg: 13.0 (4.75); 23 mg: 13.1 (4.99)	24 weeks	1434	MMSE; ACDS-ADL-sev; SIB; CIBIC-plus
Schwam and Xu 2010 [26]	MMSE 5–17	Placebo: 74; Donepezil: 73.3	Placebo: 11.97±0.34; Donepezil: 11.72±0.35	24 weeks	290	NPI; SIB; CIBIC-plus; MMSE; DAD
Homma et al. 2008 [27]	MMSE |1--12|	Placebo: 79.7±7.5; 5 mg: 78.0±8.9; 10 mg: 76.9±7.9	Placebo: 8.0±3.3; 5 mg: 7.9±3.3; 10 mg: 7.4±3.4	24 weeks	325	BEHAVE-AD; ACDS-ADL-sev; CIBIC-plus; MMSE; SIB
Black et al. 2007 [28]	MMSE |1--12|	78.0 (8.10)	Donepezil: 7.5 (325); Placebo: 7.4 (3.57)	24 weeks	343	ACDS-ADL-sev; CIBIC-plus; MMSE; SIB; NPI; CBQ